TD Cowen raised the firm’s price target on Cellebrite to $15 from $10 and keeps an Outperform rating on the shares following “strong” Q4 results highlighted by 26% revenue growth and 27% year-over-year annual recurring revenue growth. The firm sees Cellebrite as positioned for accelerated growth during 2024, the analyst added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CLBT:
- Cellebrite Announces Fourth-Quarter 2023 Results
- Cellebrite Revolutionizes Investigative Workflow with Groundbreaking End-to-End Platform to Solve More Cases Faster
- Cellebrite announces Case-to-Closure platform
- Operation Find Them All: Cellebrite Unites Philanthropic Pioneers to Accelerate Investigations of Crimes Against Children
- Cellebrite enters collaboration for investigations of crimes against children